BridgeBio Oncology Therapeutics, Inc. 10-Q filing
Filed 2025-11-12 · Report date 2025-09-30 · 2025
Filing metadata
- Accession number
- 0001193125-25-277834
- Form type
- 10-Q
- CIK
- 0001869105
- Primary document
- https://www.sec.gov/Archives/edgar/data/1869105/000119312525277834/bbot-20250930.htm
Extracted primary information
This filing includes deterministic financial metrics extracted from public filing data for BridgeBio Oncology Therapeutics, Inc..
Reported financial metrics
| Metric | Current | Prior | Change |
|---|---|---|---|
| Operating Income | $-102.4M | - | - |
| Net Income | $-95.2M | - | - |
| Eps Basic | -6.49 | - | - |
| Eps Diluted | -6.49 | - | - |
| Cash And Equivalents | $408.7M | - | - |
| Total Assets | $484.8M | - | - |
| Total Liabilities | $38.1M | - | - |
| Shareholders Equity | $446.7M | - | - |
| Operating Cash Flow | $-71.7M | - | - |
| Capital Expenditures | $533,000 | - | - |